Avanços na Terapia Genética Experimental para Restaurar a Visão

Avanços na Terapia Genética Experimental para Restaurar a Visão

aitech.pt

aitech.pt

Experimental Gene Therapy Seeks to Restore Vision by Rejuvenating Eye Neurons

Did you know that approximately 285 million people worldwide are visually impaired, with several diseases currently lacking effective treatments? A groundbreaking development in the field of biomedical science may soon change this landscape. Life Biosciences has recently received FDA approval for its experimental gene therapy ER-100. This innovative genetic treatment aims to rejuvenate damaged neurons in the eye and tackle vision loss caused by conditions like glaucoma and optic neuropathy.

What is Gene Therapy ER-100?

ER-100 is a pioneering gene therapy that utilizes a partial epigenetic reprogramming (PER) platform, developed by Life Biosciences. The therapy involves the controlled expression of three Yamanaka factors (OCT-4, SOX-2, KLF-4), collectively known as OSK, which are injected directly into the vitreous of the eye.

Mechanism of Action

The primary action of ER-100 is to modify the epigenome of retinal ganglion cells (RGCs), which are crucial for enabling communication between the eye and the brain. The role of Yamanaka factors in this process includes:

  • Cell Reprogramming: Rejuvenating damaged RGCs.
  • Cellular Function Restoration: Enhancing neuronal signaling and communication.

Objectives of ER-100 Therapy

The key goals of the ER-100 therapy include:

  • Rejuvenating Damaged Cells: Focusing on restoring the function of retinal cells that have suffered damage.
  • Addressing Biological Aging: Tackling cellular aging at its core, with the potential to develop treatments for other age-related diseases.

Clinical Trial Overview

With FDA approval, a Phase 1 clinical trial (NCT07290244) is set to commence to evaluate the safety and tolerance of ER-100 in patients suffering from open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). The trial will encompass:

  • Single Treatment Administration: Participants will receive a one-time dosage of the therapy.
  • Safety Assessments: Participants will undergo ocular examinations, laboratory tests, and analysis of biological samples (tears, saliva, feces, urine) to track how the drug is metabolized.

Preclinical Results

Preliminary studies in rodents and non-human primates have demonstrated that ER-100 can:

  • Restore methylation patterns.
  • Enhance visual function.
  • Increase optic nerve signaling.

While promising, it is important to note that the treatment cannot replace already dead cells.

Potential Side Effects

As an innovative gene therapy, considering potential side effects is crucial:

  • Localized Reactions: Inflammation at the injection site.
  • Systemic Effects: Possible adverse reactions linked to the introduction of Yamanaka factors, although no such effects have been observed in initial testing phases.

Significance of FDA Approval

This landmark approval signifies a breakthrough in cellular reprogramming research, marking the first cellular rejuvenation therapy to reach human clinical trials focused specifically on optic neuropathies. The regulatory environment suggests a cautious path for introducing similar therapies, especially as there are currently no efficacy data available from human studies since the initial focus is on safety evaluation.

Future Perspectives

Life Biosciences aims to expand its PER platform to address other age-related diseases, building upon this significant milestone. The potential for treatments for conditions beyond blindness provides new hope for both patients and researchers in the biotechnology field.

Conclusion

The ER-100 gene therapy represents a substantial advancement in genetic treatment, offering promising avenues not only in ophthalmology but also in the battle against cellular aging. With the FDA’s approval for human clinical trials, the journey toward developing new therapeutic approaches for previously incurable diseases is finally underway. While the final results of treatment in humans are still pending, continuous research may revolutionize our understanding of age-related diseases.

Sources

Share this post

Like this post? Share it with your friends!